Tagged with UK

UK A roundup of top stories from UK pharma and healthcare, including the innovative manufacturing fund comprised in the government’s new life-sciences-focused budget; GSK’s autoimmune therapy deal with Chimagen Biosciences; Northern Ireland’s potential post-Brexit drug shortages, and Oxford Biomedica’s reband as OXB.   UK to create world-first ‘early warning system’ for…

Global AstraZeneca’s Anna Litsiou, Carolyn Hynes and Allison Guy, contributing to the September 2024 edition of DIA’s Global Forum magazine, discuss the importance of improving interactions between health technology assessment (HTA) bodies and regulatory authorities.   The need to optimize drug development and facilitate faster access for patients has focused discussions…

United Kingdom The newly elected UK government’s Secretary of State for Health and Social Care Wes Streeting has a full plate of challenges ahead. Britain’s National Health Service (NHS) is plagued with a chronic lack of funding, staffing crunches and backlogs, while the country’s life sciences sector is seemingly in decline. Streeting…

Hong Kong Managing director of Otsuka Pharmaceutical Hong Kong Koji Ueda explains the Japanese company’s long-standing presence in Hong Kong, which dates back to 1956, the affiliate’s 50-50 split between pharmaceuticals and nutraceuticals and within pharma its principal focus on nephrology and CNS. Moreover, he explains the milestone launch of Otsuka’s first-in-class…

UK Throughout his long career, John-Arne Rottingen has gathered experience across multiple domains from discovery research to public health and diplomacy that led him to become the founding CEO of the Coalition for Epidemic Preparedness Innovation (CEPI). In January he took on the leadership of the UK-based foundation Wellcome, coinciding with…

UK A roundup of some of the biggest stories coming out of the UK pharma industry, including AstraZeneca’s bid for cancer specialist Fusion Pharmaceuticals; the shutdown of Sanofi’s R&D site in Cambridge; the GBP 17.9 million initiative to boster UK clinical trials, and Obsidian Therapeutics’ USD 160.5 million Series C funding raise.…

Saudi Arabia Ismail Shehada explains his decision to join leading Saudi firm Tabuk Pharmaceuticals, influenced by its potential for growth and strategic transformation in alignment with Saudi Vision 2030. He outlines the need to transition from consultancy-driven strategies to business implementation, aligning with the national agenda and achieving market leadership.   As…

UK Last year the UK-based pharma industry warned against the country’s waning competitiveness, condemning the government’s statutory scheme designed to control drug prices. UK-headquartered AstraZeneca joined the battle cry, claiming it would be choosing Ireland over Britain, a decision the company has now more than revised with a GBP 650 million…

Portugal President of the Portuguese Association Against Leukaemia (APCL), Dr Manuel Abecasis is known as the father of bone marrow transplants in Portugal. He outlines the APCL’s activities, including the organisation’s role in raising awareness and increasing the number of donars in the Portuguese Bone Marrow Donor Registry, which went from…

UK A roundup of the biggest stories from UK pharma, including the latest agreement between the British government and industry on a renewed drug pricing clawback scheme; GSK’s search for deals in China; the London-based CRO hVIVO’s new USD 21 million contract, and the latest biotech arising from Cambridge startup incubator…

United Kingdom Since its creation over 20 years ago, the National Institute for Health and Care Excellence (NICE), the Health Technology Assessment (HTA) body for England and Wales, has forged a solid reputation as one of the world’s foremost HTA authorities. Speaking at the recent FT Global Pharma and Biotech Summit, NICE…

UK Could the UK’s re-joining of Horizon Europe, the EU’s EUR 95 billion research funding programme, be the latest sign that the country is ready to win back its global scientific relevance? The announcement comes just months after an ambitious government plan to “cement” the UK’s position as a science superpower,…